Eli Lilly to buy biotechnology firm Disarm Therapeutics

This article was originally published here

The deal also allows Disarm equity-holders to secure up to $1.225bn in additional future payments for potential development, regulatory and commercial milestones based on the successful development and

The post Eli Lilly to buy biotechnology firm Disarm Therapeutics appeared first on Pharmaceutical Business review.